Merck, Addex Sign $700 Million Deal For Novel Schizophrenia Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms collaborate to develop a metabotropic glutamate receptor 5 target, a possible pathway for treatment of schizophrenia.
You may also be interested in...
Lilly’s mGlu2/3 Agonist Fails In Phase II For Schizophrenia – But So Does Zyprexa
Lilly vows to do another Phase II in effort to replicate an earlier study that showed efficacy for the novel schizophrenia drug over placebo.
Lilly’s mGlu2/3 Agonist Fails In Phase II For Schizophrenia – But So Does Zyprexa
Lilly vows to do another Phase II in effort to replicate an earlier study that showed efficacy for the novel schizophrenia drug over placebo.
HCV Among Merck’s Gains With Schering, But Future Moves Still Murky
As Merck and Schering-Plough await a potential monkey wrench from Johnson & Johnson for their merger, observers are sorting through each company's partnerships for would-be redundancies